Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib with or without darolutamide to increase PSMA PET uptake in metastatic castration-resistant prostate cancer
ACTRN12621000611820Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by St Vincent's Hospital. Started Nov 2021; status: recruiting.
02
Drugs
dasatinibdarolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ACTRN12621000611820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000611820.